Allurion Technologies Appoints Ojas Buch as Chief Operating Officer-March 2024-www.financetom.com

Allurion Technologies Appoints Ojas Buch as Chief Operating Officer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Allurion Technologies Appoints Ojas Buch as Chief Operating Officer

Jun 5, 2024 8:19 AM

10:45 AM EDT, 06/05/2024 (MT Newswires) -- Allurion Technologies ( ALUR ) said Wednesday it named Ojas Buch as chief operating officer.

The appointment was effective Monday. Buch most recently served as president of Pentax Medical, Americas.

Allurion ( ALUR ) shares fell 4% in recent trading Wednesday.

Price: 1.45, Change: -0.06, Percent Change: -3.97

Previous page： United Therapeutics Insider Sold Shares Worth $3,183,777, According to a Recent SEC Filing Next page： Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

United Therapeutics Insider Sold Shares Worth $3,183,777, According to a Recent SEC Filing

Sep 12, 2025

03:25 AM EDT, 09/12/2025 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on September 10, 2025, sold 8,000 shares in United Therapeutics ( UTHR ) for $3,183,777. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 644,489 common shares of the company, with 130 shares held directly and 644,359 controlled...

Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing

Sep 12, 2025

03:27 AM EDT, 09/12/2025 (MT Newswires) -- Mahkam Zanganeh, 10% Owner, Director, Co-Chief Executive Officer, on September 10, 2025, executed a purchase for 338,394 shares in Summit Therapeutics ( SMMT ) for $5,984,756. Following the Form 4 filing with the SEC, Zanganeh has control over a total of 591,831,532 common shares of the company, with 31,000 shares held directly and...

Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing

Sep 12, 2025

03:28 AM EDT, 09/12/2025 (MT Newswires) -- Robert W Duggan, 10% Owner, Director, Co-Chief Executive Officer, on September 10, 2025, executed a purchase for 338,394 shares in Summit Therapeutics ( SMMT ) for $5,984,756. Following the Form 4 filing with the SEC, Duggan has control over a total of 591,831,532 common shares of the company, with 556,093,090 shares held directly...

Lazard Insider Sold Shares Worth $4,240,260, According to a Recent SEC Filing

Sep 12, 2025

03:29 AM EDT, 09/12/2025 (MT Newswires) -- Evan L Russo, Chief Executive Officer of Asset Management, on September 09, 2025, sold 75,000 shares in Lazard ( LAZ ) for $4,240,260. Following the Form 4 filing with the SEC, Russo has control over a total of 227,915 common shares of the company, with 227,915 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1311370/000171748925000003/xslF345X05/wk-form4_1757633247.xml ...